Transrectal ultrasound-guided core biopsy is a widely used method to diagnose prostate cancer. It is generally considered a safe procedure but the main concern is that signi®cant complications such as infections do occur. To evaluate the effect of a combined two-dosage antibiotic prophylaxis with cipro¯oxacin and metronidazole, a prospective study of 289 patients undergoing core-biopsy of the prostate was performed. Five patients (1.7%) developed urinary tract infection and all did recover without any further complications. The infection rate was signi®cantly lower compared to our historic controls receiving no prophylaxis at all. This prophylactic regime resulted in a low infection rate and it was feasible from the patient perspective. The total cost of antibiotic medication and additional costs due to complications was 18 USD per patient and the cost-effectiveness compared to no prophylactic therapy at all was considered good.
Introduction
Transrectal ultrasound (TRUS) guided prostatic core biopsy is a well established method to diagnose prostate cancer. 1 As with all diagnostic procedures complications should be low and TRUS guided biopsy is well tolerated and generally considered a safe procedure with a fairly low morbidity. The main concern is the fact that complications such as urinary tract infections and septic infections do occur in a signi®cant number of the examined individuals. 1 ± 3 The use of antibiotic prophylaxis for transrectal prostate biopsy reduces the incidence of infective complications, but the most effective antibiotic regime is yet to be found. 4 Only a few prospective studies have yet been published but at most centres, however, short term prophylaxis is administered with onset at the time of biopsy. According to current reports, 3 such regimes do not decrease the infection rates signi®cantly and therefore we investigated the effect of two-dosage prophylaxis with cipro¯oxacin and metronidazole with the ®rst dose given 6 h prior to biopsy sampling. Health economic aspects with this regime were also considered.
Material and methods

Subjects and instruments
Between September 1992 and December 1996, 298 consecutive patients (mean age 64 y, range 47 ± 90) with the suspicion of prostatic carcinoma, underwent TRUS guided core biopsy of the prostate performed as an outpatient procedure. A Bru È l & Kjaer 1 model 1846 ultrasound scanner with a 7 MHz side-®ring (type 8537) probe was used. The core biopsies were sampled with a 18G (1.2 mm) Biopty 1 needle connected to the spring-loaded Biopty-Cut 1 device. 5 The application of this technique in prostate biopsy has been described in detail elsewere. 6 
Data collection
This study is a prospective non-randomized trial. An earlier reported study by this group 2 regarding 145 patients not given any antibiotic prophylaxis prior to or after the time of biopsy served as a historic control group. This control group was considered comparable since it did enroll a similar range of patients from the same catchment area undergoing an identical diagnostic procedure. In this present study all biopsies were sampled with the same biopsy needle in each patient, and amongst the 289 patients left for analysis a grand total of 1208 biopsies was performed (mean 4.2 needle passes/patient, range 1 ± 7 passes). No enema was given prior to the biopsy. Oral antibiotic prophylaxis with cipro¯oxacin 750 mg and metronidazole 400 mg were administered post-op 6 h prior to and 6 h after the biopsy sampling. All patients were given oral and written information of possible complications. A questionnaire concerning post-biopsy dysuria, febrile reactions, hematuria, hemospermia, additional visits to physicians, and loss of time (working and/ or leisure time) due to complications was distributed to all patients. The answer was presented to the urologist at the scheduled follow-up. If complications led to further medical attention, additional information was obtained from the patient charts. Patients with any symptoms combined with a positive urine culture were de®ned as having a post-biopsy infection.
Economical calculations
The economical calculations was based on the cost level of 1997, and the separate cost items are presented in Table 1 . The calculations of loss of working and leisure time are based on average age related hourly income. 7 From ®ndings in an earlier study, 8 we know that roughly 45% of a population of this age are still gainfully employed. The value of leisure time was estimated to be 25% of that of working time, as proposed by McGurie et al. 9 Therefore we calculated' the costs for the patients' loss of time averages 88 USD/d.
Statistical analysis
The Pearson Chi-Square test was used to examine statistical relations. The SAS JMP (SAS Institute Inc., Cary, NC, USA) software was used for statistical analysis.
Results
Of the 298 patients, one was excluded because of inadequate antibiotic administration, and eight were excluded due to lack of evaluable patient data. None of these nine patients was hospitalised according to the registers. In the remaining 289 patients representative tissue cores were obtained from all patients. In 197 (68%) of the patients the diagnosis of prostatic carcinoma was established while the remaining 92 (32%) of the patients had benign ®nd-ings. None of the patients had to discontinue antibiotic administration due to adverse reactions.
Five patients (1.7%), with a mean age of 63 y, developed urinary tract infection, Table 2 . In all cases a urine specimen was sampled at the onset of symptoms. One patient required hospitalisation for 3 d due to a urinary infection with Enterobacteriae cloacae. Blood cultures before treatment were negative but because of a high fever the patient was given parenteral antibiotics. The remaining four patients were successfully treated with oral antibiotics at an out-clinic basis. All patients recovered from the infections without any further complications and none developed acute urinary retention. Compared to the historic control group the impact of antibiotic prophylaxis on the total number of post-biopsy infections is signi®cant (P`0.001), Table 3 .
Macroscopic hematuria following biopsy occurred in 40% (117 out of 289) of the patients. In all cases the hematuria was mild and ceased spontaneously within 3 d. Transient hemospermia was reported by 31% (91 out of 289) of the patients and both hematuria and hemospermia were reported by 64 patients (22%). In this study 15 patients had diabetes mellitus, and ®ve patients were on systemic steroid medication but none of them developed urinary tract infection.
The cost of antibiotic prophylaxis was 10 USD per patient. The ®ve patients that developed urinary tract infection caused further costs. The four patients treated in the out-clinic additional antibiotic treatment of 60 (4 6 15) USD and visits to General Practioner (GP) of 520 (4 6 130) USD. The one patient that was hospitalised for three days involved expenditure of 849 (3 6 283) USD. The four patients with mild symptoms claimed a short loss of time at work due to the complication, in general one day entailing a cost of 352 (4 6 88) USD. In the single case of hospitalisation the loss of time at work was estimated to be 4 d (352 USD). The total costs due to complications was calculated to be 2133 USD or approximately 8 USD per biopsied patient and hence the overall cost for prophylactic antibiotics and complications was 18 USD per investigated patient. 
Discussion
The only important complication of TRUS guided prostatic core biopsy is infection, and death due to septicaemia has been reported after this procedure. 10 The value of antibiotics during transrectal prostate biopsy is now not in doubt but important questions about the regime remain unresolved. Theoretical considerations support the use of a combined agent which is active against both aerobes and anaerobes. The value of quinolones as an effective agent against aerobic infections has been demonstrated by several recent studies. 11, 12 Anaerobic infections following transrectal prostatic biopsy have also been reported. 10, 13 Although rare, such infections may threat the patient's life and this was the rationale for the additional use of metronidazole in this present study. We did previously report 2 an infection rate of 6.2% (9 out of 145 patients, all E.coli infections) in a series of patients not obtaining any prophylaxis at all and out of these nine patients, ®ve were hospitalised. A recent study by Enlund et al 14 did report an infection rate as low as 2.9% when no prophylaxis was used, but in their series high risk patients were excluded and reported infections were severe, that is 27% of the infected patients were hospitalised and 18% had septicaemia. In two prospective studies using short time prophylactic antibiotics installed at the time of biopsy the infection rates were reported to be 5.6 and 5.0%, respectively, 1, 33 indicating that such a design of prophylactic medication is of low bene®t. Another approach would be to offer a true prophylactic medication, that is to perform the biopsy under protection of antibiotics. Such a regime design is supported by recent reports. 11, 12 Theoretically such a regime permits a short course of treatment and may also be advantageous from the point of patient compliance as well as health economy, if shown to be ef®cient. In this present study using such a regime we veri®ed infections in 1.7% of the patients. High fever ( b 38.0 C) was observed in only two patients (0.7%) and septicaemia in none. These results are in favour of those in earlier studies which reported infections in more than 5% and septicaemia in 1 to 2% of the patients. Long term treatment may reduce the infection rate even further. Aus et al 15 reported an infection rate of less than 1.0% in a series of patients treated with nor¯oxacin during one week and with onset at the time of biopsy, but since all infections were easily treated and no case of septicaemia occurred the bene®t of prolonging the prophylactic antibiotic medication may be questioned.
In an earlier report from this group, 8 using the same basic economic assumptions as in this present study, we demonstrated a complication cost of 159 USD per biopsied patient when no prophylactic antibiotic medication was used. This ®gure should be compared to the total cost for complications and antibiotic medication of 18 USD per biopsied patient in this present study. We are convinced that prophylaxis should be of short duration, cheap, effective and if all these conditions are ful®lled a high patient compliance is likely to be the result.
Conclusion
Short-term prophylactic antibiotic medication with ciprooxacin 750 mg and metronidazole 400 mg post-op 6 h prior to and 6 h after the procedure is an effective regime in patients undergoing TRUS guided core biopsy of the prostate. This regime resulted in a low infection rate without any septicaemias and a high patient compliance. The total cost for complications and antibiotic medication was low and the cost-effectiveness compared to no prophylaxis at all was considered good. The ef®cacy of a prophylactic regime is very dif®cult to assess if the rate of complications is low and to solve the question would be a randomized placebo-controlled trial and such a study is, in progress at our department. One of the considerations in that study is if a single dose of a single drug prior to the biopsy sampling is proven effective, and if that is the case it may be considered the ultimate prophylaxis.
